NurseSavvy™
Log inSign Up

Diagnostics & Procedures · Topic 13 of 19

Bronchoscopy

Tap any line to see why it matters

Procedures · bronchoscopy

Bronchoscopy

Screen contraindications, total lidocaine across all sites, watch for pneumothorax after biopsy, then read the BAL differential.

01 · Lidocaine ceilingLidocaine total near 8 mg/kg, no single standard
02 · After biopsyTransbronchial biopsy: pneumothorax 1–6%
03 · BAL cutoffsLymphocytes > 25%, neutrophils > 50%, eos > 25%
01

Indications · contraindications

Diagnostic uses

Hemoptysis
Pneumonia: immunocompromised patient or nonresolving disease
Central masses and lung cancer staging
Diffuse lung disease (transbronchial biopsy)
Lung transplant rejection

Absolute contraindications

Acute hypercapnic respiratory failure unless intubated and ventilated
High-grade tracheal obstruction
Inability to oxygenate adequately during the procedure
Untreatable life-threatening arrhythmias
02

Retained secretions and scope choice

Secretions: chest physiotherapy, bronchodilators and suctioning first
Scope for ventilator hypoxemia or lobar atelectasis if those fail
Flexible scope: virtually all diagnostic, most therapeutic needs
Rigid scope: vigorous hemorrhage or lesions needing debulking or a stent

Rigid bronchoscopy is also used for airway dilation and some foreign bodies. Bronchoscopy for retained secretions does not replace conservative therapy; the lobar atelectasis is from impacted secretions.

03

First steps, in order

Screen for absolute contraindications
Check platelets against the lavage and biopsy thresholds
Stop clopidogrel 7 days before biopsy; continue low-dose aspirin
Topical lidocaine: lowest dose that controls cough, total across all sites
Continuous pulse oximetry, blood pressure and cardiac rhythm
04

Before: bleeding and cardiac risk

Lavage: platelets at least 20,000/µL
Biopsy: platelets at least 50,000/µL (non-US, conditional guidance)
Biopsy: hematology input on transfusion
Dual antiplatelet therapy: individualize, bleeding vs stent thrombosis
Recent MI is a relative contraindication: ideally delay 4 weeks delay 4 weeks

BTS 2013 gives > 20,000 for lavage and says to liaise with hematology before biopsy; the ≥ 50,000 biopsy number is from the 2026 Polish and 2019 Indian guidelines (conditional, low to very low-quality evidence). No current US society number was found. Don't stop dual antiplatelet therapy by default. Involve cardiology if the procedure is needed within 4–6 weeks of an MI. On anticoagulants, inspection and BAL may proceed but biopsy is not advised. If interrupting, stop warfarin 5 days before and check the INR on the procedure day; schedule DOACs at trough; bridging is not routine.

05

Anesthesia and sedation

The lidocaine limit is the total across every site

Suggested adult lidocaine ceilings sit near 8 mg/kg; no single standard
Extra lidocaine caution: older patients, hepatic or cardiac disease
Lidocaine preferred: best characterized, lower methemoglobinemia risk
Benzocaine carries FDA warnings for methemoglobinemia avoid benzocaine
IV sedation titrated so verbal contact stays possible
Midazolam preferred, with or without an opioid
Propofol only by formally trained practitioners

Lidocaine, no single standard: Indian 2019 suggests 8.0 mg/kg; 8.2 mg/kg is the older BTS 2001 figure still widely quoted; CHEST 2011 ties toxicity to > 7 mg/kg. BTS 2013 sets no cap: up to 15.4 mg/kg caused no serious events, but subjective toxicity appeared at ≥ 9.6 mg/kg. Merck limits upper-airway lidocaine to 250–300 mg in a 70-kg patient. The 4.5 mg/kg on the Wound Management sheet is for infiltration, a different route. Sedation doses are on the Procedural Sedation sheet. CHEST 2011 suggests combining a benzodiazepine with an opioid. Merck notes some centers commonly use general anesthesia or propofol deep sedation with airway control, and dexmedetomidine has been studied.

06

During: monitor and oxygenate

Give oxygen when SpO₂ falls more than 4%
Give oxygen when SpO₂ is below 90% for over 1 minute

Merck advises using supplemental oxygen during the procedure in general. BAL technique: wedge the scope in the target segment, instill 100–300 mL saline in 3–5 aliquots and retrieve at least 30%; lower return can mislead the differential, and transient hypoxemia may follow. Merck describes 50–200 mL for bronchoalveolar lavage generally; the ATS range is for cellular analysis in interstitial lung disease. On the ventilator: preoxygenate and continue 100% oxygen through recovery, use a mandatory mode, raise the pressure limit, and pass the scope through a swivel connector to preserve PEEP.

07

After: confirm and watch

After biopsy: chest radiograph for symptoms or suspicion, not routinely
After biopsy: monitor for 2 hours
Warn the patient: delayed pneumothorax can appear late
After sedation: no driving, legal signing or machinery for 24 hours

Recovery: observe 2–4 hours; recovery means a returned gag reflex and stable saturation off oxygen.

08

Complications

Overall, serious complications are uncommon

Transbronchial biopsy: pneumothorax in about 1–6%
Transbronchial biopsy: significant hemorrhage in about 1–4%
Lidocaine toxicity: dizziness, euphoria, common above 9.6 mg/kg early toxicity
Lidocaine toxicity: seizures, hypotension, arrhythmias, cardiac arrest severe toxicity
Post-bronchoscopy fever in about 5–10%, typically below 40°C
No antibiotic prophylaxis: it does not prevent post-bronchoscopy fever no prophylaxis

Serum lidocaine levels vary widely between patients at the same dose. Post-bronchoscopy fever lasts about 14 hours on average.

09

Lymphocytic or neutrophilic BAL?

LymphocytesNeutrophils
Normal share10–15%< 3%
Cellular pattern above> 15%> 3%
Cutoff pointing to a cause> 25%> 50%
SuggestsGranulomatous disease (sarcoidosis, hypersensitivity pneumonitis)Acute lung injury, aspiration or suppurative infection
10

Reading the BAL

Eosinophils over 25%: eosinophilic pneumonia
Normal nonsmoker: macrophages > 85%, eosinophils < 1%
Eosinophils over 1% define an eosinophilic pattern
Bloodier return in sequential aliquots: acute diffuse alveolar hemorrhage
Cloudy, milky fluid, sediment settling 15–20 min: alveolar proteinosis
Suspected VAP: noninvasive endotracheal aspirate preferred
Quantitative BAL under 10⁴ CFU/mL: IDSA/ATS suggest withholding antibiotics

Milky fluid with settling sediment suggests pulmonary alveolar proteinosis. 10⁴ CFU/mL is the diagnostic threshold if quantitative bronchoscopic BAL is done. Lymphocytes > 50% particularly suggest hypersensitivity pneumonitis or cellular NSIP; lymphocytosis with a CD4/CD8 ratio > 4 raises confidence in sarcoidosis when clinical features and imaging fit.

Pearl

Lidocaine's limit is the total across every site, and the lowest dose that controls the cough is the right one.

Sources · Merck Manual Professional: Bronchoscopy (Nov 2025) · Du Rand IA et al. BTS guideline for diagnostic flexible bronchoscopy in adults. Thorax 2013;68:i1–i44 · British Thoracic Society guidelines on diagnostic flexible bronchoscopy. Thorax 2001;56 Suppl 1:i1–21 · Meyer KC et al. ATS guideline: clinical utility of BAL cellular analysis in interstitial lung disease. AJRCCM 2012 · Polish Respiratory Society. Guidelines for Minimizing Bleeding Risk During Bronchoscopic Procedures. Adv Respir Med 2026 · IDSA/ATS 2016 guideline: hospital-acquired and ventilator-associated pneumonia · University of Utah Pharmacy Services alert on the FDA 2018 benzocaine methemoglobinemia warning · Guidelines for diagnostic flexible bronchoscopy in adults: Joint Indian Chest Society/National College of Chest Physicians (I)/Indian Association for Bronchology recommendations. Lung India 2019 · Wang L et al. Comparative analysis of guidelines and recommendations for sedation during flexible bronchoscopy. Eur Respir Rev 2025 · Wahidi MM et al. ACCP consensus statement on topical anesthesia, analgesia and sedation during flexible bronchoscopy. Chest 2011 · Frey WC et al. Safety of high dose lidocaine in flexible bronchoscopy (abstract) · Follow your institution's protocols.